Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C

Catrina M. Loucks; Jennifer J. Lin; Jessica N. TruemanBritt I. Dr?gem?llerGalen E. B. WrightWan‐Chun ChangKathy H. LiEric M. YoshidaJo‐Ann FordSamuel S. LeePam CrottyRichard B. KimBandar Al‐JudaibiUte I. SchwarzAlnoor RamjiJeanette F. FarivarEdward TamLori Lee WalstonColin J. D. RossBruce C. Carleton

首页> 外文期刊>Liver international >Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C

【24h】

Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C

机译：Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Abstract Background & Aims According to pivotal clinical trials, cure rates for sofosbuvir‐based antiviral therapy exceed 96%. Treatment failure is usually assumed to be because of virological resistance‐associated substitutions or clinical risk factors, yet the role of patient‐specific genetic factors has not been well explored. We determined if patient‐specific genetic factors help predict patients likely to fail sofosbuvir treatment in real‐world treatment situations. Methods We recruited sofosbuvir‐treated patients with chronic hepatitis C from five Canadian treatment sites, and performed a case‐control pharmacogenomics study assessing both previously published and novel genetic polymorphisms. Specifically studied were variants predicted to impair CES1‐dependent production of sofosbuvir’s active metabolite, interferon‐λ signalling variants expected to impact a patient’s immune response to the virus and an HLA variant associated with increased spontaneous and treatment‐induced viral clearance. Results Three hundred and fifty‐nine sofosbuvir‐treated patients were available for analyses after exclusions, with 34 (9.5%) failing treatment. We identified CES1 variants as novel predictors for treatment failure in European patients (rs115629050 or rs4513095; odds ratio (OR): 5.43; 95% confidence interval (CI): 1.64‐18.01; P?=?.0057), replicated associations with IFNL4 variants predicted to increase interferon‐λ signalling (eg rs12979860; OR: 2.25; 95% CI: 1.25‐4.06; P?=?.0071) and discovered a novel association with a coding variant predicted to enhance the activity of IFNL4's receptor (rs2834167 in IL10RB; OR: 1.81; 95% CI: 1.01‐3.24; P?=?.047). Conclusions Ultimately, this work demonstrates that patient‐specific genetic factors could be used as a tool to identify patients at higher risk of treatment failure and allow for these patients to receive effective therapy sooner.

著录项

来源
《Liver international》 |2022年第4期|796-808|共13页
作者
Catrina M. Loucks; Jennifer J. Lin; Jessica N. TruemanBritt I. Dr?gem?llerGalen E. B. WrightWan‐Chun ChangKathy H. LiEric M. YoshidaJo‐Ann FordSamuel S. LeePam CrottyRichard B. KimBandar Al‐JudaibiUte I. SchwarzAlnoor RamjiJeanette F. FarivarEdward TamLori Lee WalstonColin J. D. RossBruce C. Carleton;
展开▼
作者单位

BC Children’s Hospital Research Institute;

Department of Biochemistry and Medical Genetics,University of Manitoba;

Department of Pharmacy and Therapeutics,University of ManitobaDivision of Gastroenterology, Department of Medicine,University of British ColumbiaLiver Unit,University of Calgary Cumming School of MedicineDivision of Clinical Pharmacology, Department of Medicine,Western UniversityDivision of Transplantation,University of RochesterPacific Gastroenterology AssociatesLAIR Centre;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类内科学;
关键词
adverse drug reactions; genetics; hepatitis C; pharmacogenetics;

Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C

摘要

著录项

相关主题

期刊订阅